STOCKNO.DE
Institutional ownership intelligence
Schedule 13G/A

SRPT Schedule 13G/A filing by BlackRock

BlackRock reported beneficial ownership of 16.6M shares, representing 15.8% of Sarepta Therapeutics, Inc. in this filing.

FiledJul 30, 2026
Ownership dateJun 30, 2026
Reported shares16.6M
Reported ownership15.8%
Ownership details

Voting and dispositive power reported in the filing

These figures describe the reporting filer’s disclosed voting and investment authority. They should be read together with the reported share count and percentage.

Sole voting power 16.4M
Shared voting power 16.6M
Sole dispositive power 16.6M
Shared dispositive power 16.6M
Compared with the prior filing

How the reported position changed

This compares the current filing with the previous tracked Schedule 13 filing from the same reporting CIK for SRPT. A change between filings does not by itself establish when shares were bought or sold.

Previous filingJan 21, 2026
Reported share change+3,409,968
Ownership percentage change+3.2 pts
Previous filingThis filing
Reported shares13.2M16.6M
Reported ownership12.6%15.8%
Price context

Price dates alongside the ownership filing

Price data provides market context around the disclosure. It does not identify the filer’s actual transaction price.

Close near filing date$15.56as of Jul 30, 2026
Latest tracked price$16.39as of Aug 4, 2026
Source

Original filing and accession

Use the SEC filing as the primary source when you need the complete disclosure, footnotes, exhibits, or reporting-person details.

Reporting filer
BlackRock
CIK
CIK0002012383
Accession
0002012383-26-003144
Form
Schedule 13G/A
Read the filing in context

Understand what a Schedule 13 filing does—and does not—tell you.